Mirum Pharmaceuticals (MIRM) Reiterated at Overweight by Cantor Fitzgerald

April 10, 2026 8:01 AM

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $140.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found